Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Standard Treatment and Care Strategies

At a Glance

The primary strategy for treating Kaposi sarcoma focuses on restoring the immune system, such as using HAART for HIV-related cases or reducing immunosuppressants for transplant patients. Local therapies or systemic chemotherapy are used if the disease is advanced or affecting internal organs.

The treatment of Kaposi sarcoma (KS) is unique because it often focuses on fixing the underlying immune problem rather than just attacking the tumor itself [1][2]. Depending on your specific subtype and how much the disease has spread, your “standard of care” may range from a simple change in medication to more advanced chemotherapy [1][3].

The Strategy: Treating the Cause vs. The Tumor

The most important step in treating many types of KS is restoring or balancing your immune system [1]. In some cases, this is the only treatment needed to make the lesions shrink or disappear.

  • For Epidemic (AIDS-Related) KS: The first-line and most critical treatment is Highly Active Antiretroviral Therapy (HAART) [1][3]. By suppressing the HIV virus and raising your CD4 count, HAART allows your immune system to naturally fight the KS [1].
  • For Iatrogenic (Transplant-Related) KS: The cornerstone of care is tapering or reducing immunosuppressive drugs [4][2]. Your doctor may switch you from drugs like cyclosporine to mTOR inhibitors (such as sirolimus), which help prevent organ rejection while also actively fighting the tumor [5][6].
  • For Classic, Endemic, and Non-Epidemic KS: Because these are not typically driven by a reversible immune deficiency (like HIV or transplant medications), the primary strategy involves directly attacking the tumors using local or systemic therapies rather than immune adjustments [1][7].

Local vs. Systemic Treatment

If your KS is causing pain, swelling, or cosmetic distress, or if it has spread to internal organs, your doctor will choose between local and systemic therapies [1].

Local Therapies (For Limited Skin Disease)

These treatments target specific spots on the skin and are often used when the disease is not life-threatening but is bothersome [1][8].

  • Radiation Therapy: Highly effective for shrinking painful or visible lesions [1].
  • Electrochemotherapy: A newer technique that uses short electrical pulses to help chemotherapy (like bleomycin) enter the tumor cells more effectively [9][10].
  • Laser Therapy & Surgery: Options for very small, localized spots that need to be removed [1][8].

Systemic Therapies (For Advanced or Internal Disease)

If the KS is growing rapidly, spreading to organs like the lungs or liver, or causing severe swelling (edema), systemic treatment is necessary [11][12].

  • Pegylated Liposomal Doxorubicin (PLD): The gold-standard first-line chemotherapy for advanced KS. It is designed to stay in the bloodstream longer and target the tumor more precisely. It is important to monitor for side effects like hand-foot syndrome (redness and pain on palms/soles) and to undergo routine cardiac monitoring, as the drug can affect the heart over time [1][13].
  • Paclitaxel: A powerful second-line (and sometimes first-line) chemotherapy that is particularly effective for aggressive cases [14][12].

Common Pitfalls and “Missteps”

Because KS is rare, some doctors who don’t see it often may make common mistakes. Being aware of these can help you advocate for the right care:

  • Ignoring the Immune System: It is a major error to start chemotherapy for AIDS-related KS without first starting or optimizing HAART [1][15].
  • Misusing Steroids: Inexperienced clinicians might prescribe steroids (like prednisone) for swelling, but corticosteroids directly suppress the immune system and can cause KS lesions to rapidly grow and spread [16].
  • Misunderstanding KS-IRIS: When starting HAART for Epidemic KS, the rapid recovery of the immune system can cause a temporary, inflammatory flare-up of the lesions known as Immune Reconstitution Inflammatory Syndrome (KS-IRIS). This is a sign the immune system is waking up, not necessarily that the cancer is permanently worsening, but it requires careful management by your doctor [3].
  • Skipping the LANA-1 Test: Treatment should never begin without a biopsy that confirms HHV-8 via LANA-1 staining, as other non-cancerous conditions can look identical to KS [17][18].

Treatment Decision Guide

Subtype Primary First-Line Action When to Add Chemotherapy
Epidemic Start/Optimize HAART [1] Visceral disease or rapid skin spread [11]
Iatrogenic Reduce immunosuppression [2] Extensive disease or organ involvement [4]
Classic Observation or Local Therapy [1] Symptomatic or progressive disease [1]
Endemic Local Therapy or Chemotherapy [19] Aggressive lymph node or organ involvement [19]

Common questions in this guide

How is HIV-related Kaposi sarcoma treated?
The most important first step for AIDS-related Kaposi sarcoma is starting or optimizing Highly Active Antiretroviral Therapy (HAART). By suppressing the HIV virus and restoring your immune system, HAART allows your body to naturally fight the tumor, which is sometimes the only treatment needed.
Will I need chemotherapy for Kaposi sarcoma?
Chemotherapy is typically reserved for advanced disease, such as when lesions spread rapidly, affect internal organs, or cause severe swelling. Pegylated liposomal doxorubicin is the standard first-line systemic chemotherapy used in these more aggressive cases.
Why are steroids dangerous if I have Kaposi sarcoma?
Corticosteroids like prednisone directly suppress your immune system, which can cause Kaposi sarcoma lesions to rapidly grow and spread. Prescribing steroids for swelling is a common mistake that can significantly worsen this specific type of cancer.
What does it mean if my lesions flare up after starting HIV medication?
Immune Reconstitution Inflammatory Syndrome (KS-IRIS) is a temporary inflammatory flare-up of lesions that can happen shortly after starting HAART. It indicates your immune system is waking up and reacting to the disease, rather than a permanent worsening of the cancer.
How is Kaposi sarcoma treated in organ transplant patients?
Yes, the primary treatment for transplant-related (iatrogenic) Kaposi sarcoma involves carefully reducing your immunosuppressive drugs. Doctors often switch patients to mTOR inhibitors, which help prevent organ rejection while simultaneously fighting the tumor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my KS considered 'early-stage' (limited to skin) or 'advanced' (involving organs or lymph nodes)?
  2. 2.For my AIDS-related KS, is my current HAART regimen optimized, and do I need systemic chemotherapy now?
  3. 3.If I have Iatrogenic KS, can we safely switch my anti-rejection medications to an mTOR inhibitor like sirolimus?
  4. 4.What are the specific side effects I should expect from pegylated liposomal doxorubicin versus local radiation?
  5. 5.Is electrochemotherapy an option for my skin lesions if they are causing pain or significant cosmetic concerns?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

    Reid E, Suneja G, Ambinder RF, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2019; (17(2)):171-189.

    PMID: 30787130
  2. 2

    Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.

    Delyon J, Rabate C, Euvrard S, et al.

    Journal of the American Academy of Dermatology 2019; (81(2)):448-455 doi:10.1016/j.jaad.2019.03.028.

    PMID: 30902727
  3. 3

    [Clinical, demographic and histopathological characteristics of individuals with Kaposi's sarcoma and living with HIV in Mexico].

    Lomelí-Canedo M, Pizano-Márquez BG, Magaña-García M

    Revista medica del Instituto Mexicano del Seguro Social 2024; (62(6)):1-8.

    PMID: 39570581
  4. 4

    Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis.

    Saowapa S, Polpichai N, Siladech P, et al.

    Cureus 2024; (16(1)):e52527 doi:10.7759/cureus.52527.

    PMID: 38371002
  5. 5

    Posttransplant Kaposi sarcoma: Analysis of a series of 13 patients.

    González-Cruz C, Ferrándiz-Pulido C, Ferrer Fàbregas B, García-Patos Briones V

    Medicina clinica 2021; (157(7)):339-343 doi:10.1016/j.medcli.2021.04.030.

    PMID: 34246484
  6. 6

    Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging.

    Hernández-Sierra A, Rovira J, Petit A, et al.

    Transplant international : official journal of the European Society for Organ Transplantation 2016; (29(9)):1008-16 doi:10.1111/tri.12800.

    PMID: 27208691
  7. 7

    Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022.

    Morales AE, Benson G, Glavan S, et al.

    The oncologist 2025; (30(3)) doi:10.1093/oncolo/oyaf024.

    PMID: 40079529
  8. 8

    Laser Therapy Approaches in the Treatment of Kaposi's Sarcoma: A Comprehensive Review of Dermatologic Options.

    Battilotti C, Cassalia F, Svara F, et al.

    Dermatology practical & conceptual 2025; (15(3)) doi:10.5826/dpc.1503a5332.

    PMID: 40790410
  9. 9

    Electrochemotherapy in Kaposi's Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions.

    Rullo V, Castellaneta F, D'Antonio S, et al.

    Cancers 2024; (16(7)) doi:10.3390/cancers16071295.

    PMID: 38610972
  10. 10

    Electrochemotherapy for cutaneous Kaposi Sarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT).

    Quaglino P, Brizio M, Bertino G, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025; (51(8)):110099 doi:10.1016/j.ejso.2025.110099.

    PMID: 40347711
  11. 11

    Pleural Kaposi Sarcoma in Two HIV-Positive Patients.

    Abou Hamdan D, Hayek G, Abi Hanna P, et al.

    Cureus 2024; (16(7)):e64938 doi:10.7759/cureus.64938.

    PMID: 39156295
  12. 12

    Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis.

    Freeman EE, McCann NC, Semeere A, et al.

    The Lancet. Global health 2022; (10(8)):e1179-e1188 doi:10.1016/S2214-109X(22)00242-X.

    PMID: 35839816
  13. 13

    Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin.

    Chapola JC, Kleber SL, Krown SE, Painschab M

    Cost effectiveness and resource allocation : C/E 2025; (23(1)):78 doi:10.1186/s12962-025-00677-x.

    PMID: 41286911
  14. 14

    Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.

    Krown SE, Moser CB, MacPhail P, et al.

    Lancet (London, England) 2020; (395(10231)):1195-1207 doi:10.1016/S0140-6736(19)33222-2.

    PMID: 32145827
  15. 15

    Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015.

    Poizot-Martin I, Obry-Roguet V, Duvivier C, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(5)):1065-1073 doi:10.1111/jdv.16204.

    PMID: 31953902
  16. 16

    Steroids are a risk factor for Kaposi's sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection.

    Fernández-Sánchez M, Iglesias MC, Ablanedo-Terrazas Y, et al.

    AIDS (London, England) 2016; (30(6)):909-14 doi:10.1097/QAD.0000000000000993.

    PMID: 26636923
  17. 17

    A Series of Patients with Kaposi Sarcoma (Mediterranean/Classical Type): Case Presentations and Short Update on Pathogenesis and Treatment.

    Temelkova I, Tronnier M, Terziev I, et al.

    Open access Macedonian journal of medical sciences 2018; (6(9)):1688-1693 doi:10.3889/oamjms.2018.354.

    PMID: 30337990
  18. 18

    Kaposi's Sarcoma. A Case Report.

    Polách O, Kopecký A, Wandrolová Z, et al.

    Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti 2024; (80(2)):114-118 doi:10.31348/2024/16.

    PMID: 38531684
  19. 19

    Endemic Kaposi's Sarcoma.

    Zeinaty PE, Lebbé C, Delyon J

    Cancers 2023; (15(3)) doi:10.3390/cancers15030872.

    PMID: 36765830

This page provides general educational information about Kaposi sarcoma treatment strategies. Always consult your oncologist or infectious disease specialist to determine the most appropriate and safe treatment plan for your specific subtype.

Get notified when new evidence is published on Kaposi sarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.